Condition
HER2-positive Advanced Breast Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 4 HER2-positive Advanced Breast Cancer clinical trials that are recruiting, at sites in 7 countries (most in China (3), Australia (1), Brazil (1)). By phase: Phase 3 (1), Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 7Countries
Newest HER2-positive Advanced Breast Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Trastuzumab rezetecan with or without radiotherapy for HER2‑positive advanced breast cancer that has spread to the brain. | Phase 2 | Zhengzhou, Henan | Recruiting | Aug 3, 2025 |
| TQB2930 plus chemotherapy for HER2-positive advanced breast cancer | Phase 3 | Bengbu, Anhui and 74 other locations | Recruiting | Jul 2, 2025 |
| Evaluating BBO-10203 for advanced solid tumors | Phase 1 | Duarte, California and 43 other locations | Recruiting | Oct 3, 2024 |
| Combining inetetamab, pyrotinib, and vinorelbine for treating advanced HER2-positive breast cancer | — | Hangzhou, Zhejiang | Recruiting | May 12, 2023 |
All recruiting trials (4)
-
Trastuzumab rezetecan with or without radiotherapy for HER2‑positive advanced breast cancer that has spread to the brain.
This trial will test whether adding radiotherapy to trastuzumab rezetecan helps adults with HER2‑positive advanced breast cancer and untreated brain metastases control their brain tumors better than the drug alone.
-
TQB2930 plus chemotherapy for HER2-positive advanced breast cancer
This study tests whether TQB2930 with chemotherapy works better than trastuzumab with chemotherapy for people with HER2-positive advanced breast cancer who have already had at least two anti-HER2 treatments.
-
Evaluating BBO-10203 for advanced solid tumors
This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.
-
Combining inetetamab, pyrotinib, and vinorelbine for treating advanced HER2-positive breast cancer
This study is testing a new combination of three drugs to see if they can help people with advanced HER2-positive breast cancer feel better and live longer.
Related topics
Quick answers
How many HER2-positive Advanced Breast Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in China (3 trials), Australia (1 trial), Brazil (1 trial), France (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.